Phase I study of liposomal daunorubicin in patients with acute leukemia

Jorge Cortes, Susan O'Brien, Elihu Estey, Francis Giles, Michael Keating, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

The dose of anthracyclines used during induction has been identified as a significant prognostic factor in acute leukemias. Liposomal encapsulation of anthracyclines has been proposed as a way of decreasing toxicity and probably increasing efficacy of these agents, therefore allowing the exploration of high-dose anthracycline therapy in acute leukemias. We conducted a phase I study of liposomal daunorubicin (Daunoxome®; DNX) in patients with refractory or relapsed acute leukemias. Patients received three daily doses of DNX at 75, 100, 150 or 200 mg/m2 on each cycle, to a total dose of 225, 300, 450, and 600 mg/m2, respectively. At least three patients were included at each dose level before escalating to the next level, and patients could receive more than one course at the next dose level. Twenty-four patients were included and 23 are evaluable. Fifteen patients received one course, seven received two courses, and one received three courses of DNX. Seventeen patients had previously received anthracyclines. The dose-limiting toxicity was mucositis which occurred (grade 3-4) in 3 of 5 patients treated at 200 mg/m2, 2 of 9 treated at 150 mg/m2 and 1 of 6 at 100 mg/m2. Other non-hematologic toxicity was mild and infrequent. There was no change in post-LVEF among 9 patients with available data and no significant cardiac events were documented. Two patients had a complete response: one patient with chronic myeloid leukemia in refractory blast phase went back to chronic phase, and one patient with second relapse acute promyelocytic leukemia achieved a third complete remission. We conclude that the maximally tolerated dose of DNX in this schedule is 150 mg/m2 and has significant anti-leukemia activity.

Original languageEnglish (US)
Pages (from-to)81-87
Number of pages7
JournalInvestigational New Drugs
Volume17
Issue number1
DOIs
StatePublished - Oct 6 1999
Externally publishedYes

Fingerprint

Daunorubicin
Leukemia
Anthracyclines
Blast Crisis
Acute Promyelocytic Leukemia
Mucositis
Maximum Tolerated Dose
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Appointments and Schedules

Keywords

  • Acute leukemia
  • Liposomal daunorubicin
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase I study of liposomal daunorubicin in patients with acute leukemia. / Cortes, Jorge; O'Brien, Susan; Estey, Elihu; Giles, Francis; Keating, Michael; Kantarjian, Hagop.

In: Investigational New Drugs, Vol. 17, No. 1, 06.10.1999, p. 81-87.

Research output: Contribution to journalArticle

Cortes, J, O'Brien, S, Estey, E, Giles, F, Keating, M & Kantarjian, H 1999, 'Phase I study of liposomal daunorubicin in patients with acute leukemia', Investigational New Drugs, vol. 17, no. 1, pp. 81-87. https://doi.org/10.1023/A:1006216001681
Cortes, Jorge ; O'Brien, Susan ; Estey, Elihu ; Giles, Francis ; Keating, Michael ; Kantarjian, Hagop. / Phase I study of liposomal daunorubicin in patients with acute leukemia. In: Investigational New Drugs. 1999 ; Vol. 17, No. 1. pp. 81-87.
@article{6ae3fac6e8d34443b05a5a2226deaf71,
title = "Phase I study of liposomal daunorubicin in patients with acute leukemia",
abstract = "The dose of anthracyclines used during induction has been identified as a significant prognostic factor in acute leukemias. Liposomal encapsulation of anthracyclines has been proposed as a way of decreasing toxicity and probably increasing efficacy of these agents, therefore allowing the exploration of high-dose anthracycline therapy in acute leukemias. We conducted a phase I study of liposomal daunorubicin (Daunoxome{\circledR}; DNX) in patients with refractory or relapsed acute leukemias. Patients received three daily doses of DNX at 75, 100, 150 or 200 mg/m2 on each cycle, to a total dose of 225, 300, 450, and 600 mg/m2, respectively. At least three patients were included at each dose level before escalating to the next level, and patients could receive more than one course at the next dose level. Twenty-four patients were included and 23 are evaluable. Fifteen patients received one course, seven received two courses, and one received three courses of DNX. Seventeen patients had previously received anthracyclines. The dose-limiting toxicity was mucositis which occurred (grade 3-4) in 3 of 5 patients treated at 200 mg/m2, 2 of 9 treated at 150 mg/m2 and 1 of 6 at 100 mg/m2. Other non-hematologic toxicity was mild and infrequent. There was no change in post-LVEF among 9 patients with available data and no significant cardiac events were documented. Two patients had a complete response: one patient with chronic myeloid leukemia in refractory blast phase went back to chronic phase, and one patient with second relapse acute promyelocytic leukemia achieved a third complete remission. We conclude that the maximally tolerated dose of DNX in this schedule is 150 mg/m2 and has significant anti-leukemia activity.",
keywords = "Acute leukemia, Liposomal daunorubicin, Phase I",
author = "Jorge Cortes and Susan O'Brien and Elihu Estey and Francis Giles and Michael Keating and Hagop Kantarjian",
year = "1999",
month = "10",
day = "6",
doi = "10.1023/A:1006216001681",
language = "English (US)",
volume = "17",
pages = "81--87",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase I study of liposomal daunorubicin in patients with acute leukemia

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Estey, Elihu

AU - Giles, Francis

AU - Keating, Michael

AU - Kantarjian, Hagop

PY - 1999/10/6

Y1 - 1999/10/6

N2 - The dose of anthracyclines used during induction has been identified as a significant prognostic factor in acute leukemias. Liposomal encapsulation of anthracyclines has been proposed as a way of decreasing toxicity and probably increasing efficacy of these agents, therefore allowing the exploration of high-dose anthracycline therapy in acute leukemias. We conducted a phase I study of liposomal daunorubicin (Daunoxome®; DNX) in patients with refractory or relapsed acute leukemias. Patients received three daily doses of DNX at 75, 100, 150 or 200 mg/m2 on each cycle, to a total dose of 225, 300, 450, and 600 mg/m2, respectively. At least three patients were included at each dose level before escalating to the next level, and patients could receive more than one course at the next dose level. Twenty-four patients were included and 23 are evaluable. Fifteen patients received one course, seven received two courses, and one received three courses of DNX. Seventeen patients had previously received anthracyclines. The dose-limiting toxicity was mucositis which occurred (grade 3-4) in 3 of 5 patients treated at 200 mg/m2, 2 of 9 treated at 150 mg/m2 and 1 of 6 at 100 mg/m2. Other non-hematologic toxicity was mild and infrequent. There was no change in post-LVEF among 9 patients with available data and no significant cardiac events were documented. Two patients had a complete response: one patient with chronic myeloid leukemia in refractory blast phase went back to chronic phase, and one patient with second relapse acute promyelocytic leukemia achieved a third complete remission. We conclude that the maximally tolerated dose of DNX in this schedule is 150 mg/m2 and has significant anti-leukemia activity.

AB - The dose of anthracyclines used during induction has been identified as a significant prognostic factor in acute leukemias. Liposomal encapsulation of anthracyclines has been proposed as a way of decreasing toxicity and probably increasing efficacy of these agents, therefore allowing the exploration of high-dose anthracycline therapy in acute leukemias. We conducted a phase I study of liposomal daunorubicin (Daunoxome®; DNX) in patients with refractory or relapsed acute leukemias. Patients received three daily doses of DNX at 75, 100, 150 or 200 mg/m2 on each cycle, to a total dose of 225, 300, 450, and 600 mg/m2, respectively. At least three patients were included at each dose level before escalating to the next level, and patients could receive more than one course at the next dose level. Twenty-four patients were included and 23 are evaluable. Fifteen patients received one course, seven received two courses, and one received three courses of DNX. Seventeen patients had previously received anthracyclines. The dose-limiting toxicity was mucositis which occurred (grade 3-4) in 3 of 5 patients treated at 200 mg/m2, 2 of 9 treated at 150 mg/m2 and 1 of 6 at 100 mg/m2. Other non-hematologic toxicity was mild and infrequent. There was no change in post-LVEF among 9 patients with available data and no significant cardiac events were documented. Two patients had a complete response: one patient with chronic myeloid leukemia in refractory blast phase went back to chronic phase, and one patient with second relapse acute promyelocytic leukemia achieved a third complete remission. We conclude that the maximally tolerated dose of DNX in this schedule is 150 mg/m2 and has significant anti-leukemia activity.

KW - Acute leukemia

KW - Liposomal daunorubicin

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=0032845069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032845069&partnerID=8YFLogxK

U2 - 10.1023/A:1006216001681

DO - 10.1023/A:1006216001681

M3 - Article

C2 - 10555126

AN - SCOPUS:0032845069

VL - 17

SP - 81

EP - 87

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -